Latest Breaking News On - Myogen inc - Page 1 : comparemela.com

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announcedthat during its meeting of 26 March 2024, t.

Galapagos NV: Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Christopher Graybill Joins ARCA as Vice President, Clinical

Christopher Graybill Joins ARCA as Vice President, Clinical Development May 05, 2021 16:05 ET | Source: ARCA biopharma, Inc. ARCA biopharma, Inc. Westminster, Colorado, UNITED STATES WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are delighted to welcome Christopher to ARCA as Vice President of Clinical Development. His over 14 years of experience in the biotechnology and medical device industries, supporting global clinical strategy, clinical trial planning and conduct, and other aspects of product development including in the cardiovascular space, will be a